Key result
Recurrent VTE (HR 1.52; 95% CI 1.16-2.00), major bleeding (HR 1.82), and CRNMB (HR 1.38) each significantly increased all-cause mortality in cancer patients receiving anticoagulation for VTE.
Why the study?
The study aimed to determine the impact of VTE recurrence and anticoagulant-related bleeding on all-cause mortality in patients with cancer-associated VTE.
Do VTE recurrence and anticoagulant-related bleeding increase all-cause mortality in cancer patients receiving anticoagulation for acute VTE?
Population
1,812 consecutive cancer patients with acute VTE treated with anticoagulants
Comparison
Impact of VTE recurrence, major bleeding, and CRNMB on all-cause mortality
Design
Cohort analysis of prospectively collected data
Authors
Loading...
May increase mortality risk from recurrence or bleeding in cancer VTE; leaves open optimal strategies pending randomized data.
Cohort (n=1,812)
Do VTE recurrence and anticoagulant-related bleeding increase all-cause mortality in cancer patients receiving anticoagulation for acute VTE?
Hazard Ratio: 1.52 (95% CI 1.16–2)
p-value: p=0.0028
In cancer patients receiving anticoagulation for VTE, the occurrence of recurrent VTE, major bleeding, or clinically relevant nonmajor bleeding significantly increases the risk of all-cause mortality by 40% to 80%.
McBane et al. (2022) conducted a cohort in cancer-associated venous thromboembolism (VTE) (n=1,812). Recurrent VTE, major bleeding, and clinically relevant nonmajor bleeding vs. No recurrence or bleeding was evaluated on all-cause mortality (HR 1.52, 95% CI 1.16-2.00, p=0.0028). Recurrent VTE (HR 1.52; 95% CI 1.16-2.00), major bleeding (HR 1.82), and CRNMB (HR 1.38) each significantly increased all-cause mortality in cancer patients receiving anticoagulation for VTE.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: